Hagen Kennecke (@hkennecke) 's Twitter Profile
Hagen Kennecke

@hkennecke

GI and NET Oncologist, @OHSU Knight Cancer Institute, Chief & Med Dir CHO and Knight-Legacy Collaborative, Dad, cycling & ski enthusiast!

ID: 2378288102

calendar_today08-03-2014 06:54:27

1,1K Tweet

1,1K Followers

445 Following

Emil Lou, MD, PhD, FACP (@cancerassassin1) 's Twitter Profile Photo

Coming in to #ASCO24, it was obvious that ADCs were a #hottopic, but they are truly inescapable: in every direction, in seemingly every tumor type, they are being investigated and taking center stage (literally). ADCs have progressed to Generation Next: let's see what it brings.

Mark Lewis, MD, FASCO (@marklewismd) 's Twitter Profile Photo

Treatment has to be TOLERABLE before it can be EFFECTIVE (even allowing for the understandable difficulty healing in time for adjuvant FLOT, I don't understand the ~1/3rd of patients who couldn't complete pre-op in CROSS, especially when it was <10% over a decade ago!) #ASCO24

Treatment has to be TOLERABLE before it can be EFFECTIVE (even allowing for the understandable difficulty healing in time for adjuvant FLOT, I don't understand the ~1/3rd of patients who couldn't complete pre-op in CROSS, especially when it was &lt;10% over a decade ago!) #ASCO24
Dr. Cathy Eng (@cathyengmd) 's Twitter Profile Photo

EA#2174 NCI CTEP Clinical Research: A phase II/III study of perioperative nivo/ipi in locally adv esophageal and GEJ adenoCA. Though NS benefit for pCR (21% vs. 24.8%). 👏Dr. Jennifer Eads Penn Medicine - Abramson Cancer Center for discussing the IMP of #cancerresearch in #rarecancers. ECOG-ACRIN Cancer Research Group #ASCO24 @asco

EA#2174 <a href="/NCICTEP_ClinRes/">NCI CTEP Clinical Research</a>: A phase II/III study of perioperative nivo/ipi in locally adv esophageal and GEJ adenoCA.  Though NS benefit for pCR (21% vs. 24.8%). 👏Dr. Jennifer Eads <a href="/PennCancer/">Penn Medicine - Abramson Cancer Center</a> for discussing the IMP of #cancerresearch in #rarecancers. <a href="/eaonc/">ECOG-ACRIN Cancer Research Group</a> #ASCO24 @asco
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

#ASCO24: GIANT study results show no difference in OS and high Gr3/4 toxicity in both dose-reduced chemo arms. Study demonstrates the role of chemotherapy in this patient population. ⁦Efrat Dotan MD⁩ ⁦OncoAlert

#ASCO24: GIANT study results show no difference in OS and high Gr3/4 toxicity in both dose-reduced chemo arms. Study demonstrates the role of chemotherapy in this patient population. ⁦<a href="/efratdotan/">Efrat Dotan MD</a>⁩ ⁦<a href="/OncoAlert/">OncoAlert</a>⁩
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

#ASCO24: NRG 0848 final results show no benefit of added post-op CRT to historic chemo in R1 PDAC but possible benefit in pN0. Future trials of post-op CRT with modern adjuvant chemo are planned. ⁦Dr. Nina Niu Sanford⁩ ⁦NRG Oncology⁩ ⁦

#ASCO24: NRG 0848 final results show no benefit of added post-op CRT to historic chemo in R1 PDAC but possible benefit in pN0. Future trials of post-op CRT with modern adjuvant chemo are planned. ⁦<a href="/NiuSanford/">Dr. Nina Niu Sanford</a>⁩ ⁦<a href="/NRGonc/">NRG Oncology</a>⁩ ⁦
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

#ASCO24: Mature CHECKMATE 90W IPI3/NIVO1 in unresectable #HCC vs TKI had significantly improved OS and RR of 36%. Another 1st line option. 29% use of high dose steroids for immune AEs. ⁦OncoAlert⁩ ⁦Dr. Cathy EngLaura Goff⁩⁩ ⁦Syed A. Ahmad

#ASCO24: Mature CHECKMATE 90W IPI3/NIVO1 in unresectable #HCC vs TKI had significantly improved OS and RR of 36%. Another 1st line option. 29% use of high dose steroids for immune AEs. ⁦<a href="/OncoAlert/">OncoAlert</a>⁩ ⁦<a href="/CathyEngMD/">Dr. Cathy Eng</a> ⁩ <a href="/drlauragoff/">Laura Goff</a>⁩⁩ ⁦<a href="/SyedAAhmad5/">Syed A. Ahmad</a>⁩
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

NICHE-2 published in NEJM —what an elegant work from super star Myriam Chalabi and senior John Haanen ! Study presented #ESMO22 and started the hashtag #ChalabiPlot => near 100% pathologic response in dMMR colon cancer! OncoAlert

NICHE-2 published in <a href="/NEJM/">NEJM</a> —what an elegant work from super star <a href="/MyriamChalabi/">Myriam Chalabi</a> and senior <a href="/HaanenJohn/">John Haanen</a> ! Study presented #ESMO22 and started the hashtag #ChalabiPlot =&gt; near 100% pathologic response in dMMR colon cancer! <a href="/OncoAlert/">OncoAlert</a>
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated #coloncancer, OS HR=0.4. Patients are asking: do we recommend COX-2 for the 20% with mut PIK3CA❓ Need to do NGS for all stage III CRC. Journal of Clinical Oncology

First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated #coloncancer, OS HR=0.4. 

Patients are asking: do we recommend COX-2 for the 20% with mut PIK3CA❓

Need to do NGS for all stage III CRC.  <a href="/JCO_ASCO/">Journal of Clinical Oncology</a>
NET CONNECT (@net_connectinfo) 's Twitter Profile Photo

🌍🔬 The 2024 ENETS guidance paper for managing well-differentiated small intestine neuroendocrine tumours (#Si-NET) is out! It emphasises the importance of adequate biochemical assessment, staging, and multidisciplinary treatment decisions. #MedEd ow.ly/USu150Syga9

🌍🔬 The 2024 ENETS guidance paper for managing well-differentiated small intestine neuroendocrine tumours (#Si-NET) is out! It emphasises the importance of adequate biochemical assessment, staging, and multidisciplinary treatment decisions.

#MedEd

ow.ly/USu150Syga9
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

SWOG Cancer Research Network⁩ AIMS #rectalcancer trial results: The diet modification intervention significantly reduced LARS - mean scores ⬇️ from Major to Minor. This could help patients with LARS. ⁦⁦Jason Zell⁩ ⁦⁦⁦COLONTOWN⁩ ⁦Fight Colorectal Cancer⁩ search.app/iXob3FRYasPZMK…

Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

We have data now to personalize #rectalcancer treatment. Based on tumor factors and patient preferences. Gone are the days where most patients are treated the same way. These ⁦ASCO⁩ guidelines should help! ascopubs.org/doi/10.1200/JC…

Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

Summertime is fire time in the Columbia River Gorge. Stay fire 🔥 safe! Not quite like the romantic commuter pics posted by ⁦Thor Halfdanarson⁩, but still beautiful here!

Summertime is fire time in the Columbia River Gorge. Stay fire 🔥 safe!    

Not quite like the romantic commuter pics posted by ⁦<a href="/OncoThor/">Thor Halfdanarson</a>⁩, but still beautiful here!
Hagen Kennecke (@hkennecke) 's Twitter Profile Photo

Very cool cross-trial comparison of 1st line PD1 + CTLA-4 versus PD1 + LAG-3 strategy (in advanced melanoma). Similar efficacy but slightly better safety with LAG-3 combo. Journal of Clinical Oncology Improves our understanding of the 3rd CPI. OncoAlert ascopubs.org/doi/full/10.12…

Syed A. Ahmad (@syedaahmad5) 's Twitter Profile Photo

Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum ⁦AnnalsSurgOncology⁩ link.springer.com/article/10.124…